NeuroRx has the potential to build a pipeline of novel CNS-focused therapeutics. We believe that our leadership in the science of the N-methyl-D-asparate (NMDA) receptor, and how it may affect various disorders marked by depression, strongly positions us to pursue additional indications.
Our initial focus on Acute Suicidal Ideation/Behavior (ASIB) in Bipolar Depression. Thereafter the company plans to expand into ASIB in major depressive disorder (MDD). Other potential indications include chronic depression, post-traumatic stress disorder and bipolar depression marked by a less acute level of suicide risk.
Based on our scientific leadership around the NMDA receptor,
NeuroRx has the
potential to build a
pipeline of novel,